Kitov Pharma Ltd. is a clinical-stage company dedicated to developing innovative therapies to combat tumor immune evasion and drug resistance in cancer treatment. Their pipeline includes NT219, a small molecule targeting cancer drug resistance pathways, which is being developed as a monotherapy and combination therapy with cetuximab for advanced solid tumors and head and neck cancer. The company is also working on CM24, a monoclonal antibody blocking CEACAM1, a novel immune checkpoint that supports tumor immune evasion and survival, which is being developed as a combination therapy with anti-PD1 checkpoint inhibitors for non-small cell lung cancer and pancreatic cancer.